Skip to main content

Advertisement

SpringerLink
Log in

Adiponectin: Systemic contributor to insulin sensitivity

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Adipocyte-specific secreted molecules, termed adipokines, have dispelled the notion of adipose tissue as an inert storage depot for lipids, and highlighted its role as an active endocrine organ that monitors and alters whole-body metabolism and maintains energy homeostasis. One of these adipokines, adiponectin (also known as Acrp30, AdipoQ, and GBP28), has gained significant attention recently as a mediator of insulin sensitivity. Many clinical reports and genetic studies over the past few years demonstrate decreased circulating levels of this hormone in metabolic dysfunction, such as obesity and insulin resistance, in both humans and animal models. Pharmacologic adiponectin treatments in rodents increase insulin sensitivity, although the primary site and detailed mechanism of action is yet to be determined. The phenotypes of adiponectin-deficient and transgenic adiponectin-overproducing animal models underscore the role of adiponectin in the maintenance of glucose and lipid homeostasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001, 104:531–543.

    Article  PubMed  CAS  Google Scholar 

  2. Matsuzawa Y, Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N YAcad Sci 1999, 892:146–154.

    Article  CAS  Google Scholar 

  3. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.

    Article  PubMed  CAS  Google Scholar 

  4. Combs TP, Berg AH, Obici S, et al.: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2002, 108:1875–1881. Confirmation that the mechanism of action of full-length, mammalian-purified adiponectin is through its actions on liver. The use of pancreatic euglycemic clamps demonstrated that with infusion of recombinant adiponectin, hepatic gluconeogenesis is significantly inhibited owing to decreased hepatic expression of phosphoenolpyruvate carboxylase and glucose-6-phosphatase.

    Article  Google Scholar 

  5. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79–83.

    Article  PubMed  CAS  Google Scholar 

  6. Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595–1599.

    PubMed  CAS  Google Scholar 

  7. Yang WS, Lee WJ, Funahashi T, et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86:3815–3819.

    Article  PubMed  CAS  Google Scholar 

  8. Fasshauer M, Klein J, Neumann S, et al.: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290:1084–1089.

    Article  PubMed  CAS  Google Scholar 

  9. Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002, 147:173–180.

    Article  PubMed  CAS  Google Scholar 

  10. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930–1935.

    Article  PubMed  CAS  Google Scholar 

  11. Lindsay RS, Funahashi T, Hanson RL, et al.: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57–58. One of the better longitudinal studies using cohorts of Pima Indians, demonstrating the prospective use of adiponectin serum levels to determine future risk of development of type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  12. Vozarova B, Stefan N, Lindsay RS, et al.: Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002, 51:2964–2967.

    Article  PubMed  CAS  Google Scholar 

  13. Stefan N, Vozarova B, Funahashi T, et al.: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884–1888.

    Article  PubMed  CAS  Google Scholar 

  14. Kanety H, Moshe S, Shafrir E, et al.: Hyperinsulinemia induces a reversible impairment in insulin receptor function leading to diabetes in the sand rat model of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994, 91:1853–1857.

    Article  PubMed  CAS  Google Scholar 

  15. Storgaard H, SongXM, Jensen CB, et al.: Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected]. Diabetes 2001, 50:2770–2778.

    Article  PubMed  CAS  Google Scholar 

  16. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311–320.

    PubMed  CAS  Google Scholar 

  17. Hotta K, Funahashi T, Bodkin NL, et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126–1133. Another demonstration of longitudinal changes in plasma adiponectin levels during development of obesity and type 2 diabetes. Shows an association between adiponectin and insulin resistance independent of obesity in a primate diabetic model. Specifically, when obese monkeys were stratified into high-adiponectin and low-adiponectin groups according to BMI, hypoadiponectinemic monkeys with decreased BMI were more insulin resistant than hyperadiponectinemic animals with increased BMI.

    Article  PubMed  CAS  Google Scholar 

  18. Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005–2010. The first report of recombinant, bioactive adiponectin. Recombinant gAdiponectin is produced from bacteria and injected into rodents, leading to increased muscle fatty acid oxidation and weight loss following more chronic administration. Although many groups do not visualize an apparent cleavage form of adiponectin this group can detect from human serum, this study demonstrates the pharmacologic potential of an adiponectin-like molecule.

    Article  PubMed  CAS  Google Scholar 

  19. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941–946. Extension of the work performed by Fruebis et al. [18], demonstrating that pharmacologic doses of gAdiponectin can ameliorate insulin resistance in mouse models of obesity and type 2 diabetes, confirming the potential of this ligand as a possible pharmaceutical target.

    Article  PubMed  CAS  Google Scholar 

  20. Berg AH, Combs T, Du X, et al.: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947–953. Initial report of the use of recombinant adiponectin synthesized from mammalian cells. The authors demonstrate that a single injection of purified material, leading to a two- to threefold elevation of circulating levels, causes a significant, transient decrease in serum glucose in wild-type animals, and correspondingly greater decreases in models of type 1 and 2 diabetes. Furthermore, this result is confirmed with in vitro experiments on isolated hepatocytes, showing a novel mechanism for adiponectin function.

    Article  PubMed  CAS  Google Scholar 

  21. Wang Y, Xu A, Knight C, et al.: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulinsensitizing activity. J Biol Chem 2002, 277:19521–19529.

    Article  PubMed  CAS  Google Scholar 

  22. Pajvani UB, Combs TP, Berg AH, et al.: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073–9085.

    Article  PubMed  CAS  Google Scholar 

  23. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87:377–389.

    Article  PubMed  CAS  Google Scholar 

  24. Berger J, Leibowitz MD, Doebber TW, et al.: Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999, 274:6718–6725.

    Article  PubMed  CAS  Google Scholar 

  25. Kersten S, Wahli W: Peroxisome proliferator activated receptor agonists. EXS 2000, 89:141–151.

    PubMed  CAS  Google Scholar 

  26. Barroso I, Gurnell M, Crowley VE, et al.: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880–883.

    PubMed  CAS  Google Scholar 

  27. Chao L, Marcus-Samuels B, Mason MM, et al.: Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000, 106:1221–1228.

    Article  PubMed  CAS  Google Scholar 

  28. Maeda N, Takahashi M, Funahashi T, et al.: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094–2099. Initial demonstration of increased, dose-dependent adiponectin synthesis and secretion in both humans and rodents in vivo following administration of TZDs.

    Article  PubMed  CAS  Google Scholar 

  29. Combs TP, Wagner JA, Berger J, et al.: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002, 143:998–1007.

    Article  PubMed  CAS  Google Scholar 

  30. Hirose H, Kawai T, Yamamoto Y, et al.: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002, 51:314–317.

    Article  PubMed  CAS  Google Scholar 

  31. Jiang G, Dallas-Yang Q, Li Z, et al.: Potentiation of insulin signaling in tissues of Zucker obese rats after acute and longterm treatment with PPARgamma agonists. Diabetes 2002, 51:2412–2419.

    Article  PubMed  CAS  Google Scholar 

  32. Yu JG, Javorschi S, Hevener AL, et al.: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968–2974.

    Article  PubMed  CAS  Google Scholar 

  33. Kubota N, Terauchi Y, Yamauchi T, et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863–25866. Early characterization of adiponectin-deficient animals demonstrating moderate insulin resistance with glucose intolerance despite similar total adiposity; in addition, this paper demonstrates increased neointimal formation in response to vascular cuff injury, possibly indicative of antiatherosclerotic properties of adiponectin in vivo.

    Article  PubMed  CAS  Google Scholar 

  34. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731–737. A more complete report detailing metabolic phenotype of adiponectin knockout. This study, besides confirmation of insulin-resistant phenotype demonstrated by Kubota et al. [33], details delayed FFA clearance in serum and provides a possible mechanism by showing increased serum tumor necrosis factor α and decreased FATP-1 expression in muscle.

    Article  PubMed  CAS  Google Scholar 

  35. Ma K, Cabrero A, Saha PK, et al.: Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002, 277:34658–34661.

    Article  PubMed  CAS  Google Scholar 

  36. Yamauchi T, Kamon J, Waki H, et al.: Globular adiponectin protected ob/ob mice from diabetes and apoE deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461–2468.

    Article  PubMed  CAS  Google Scholar 

  37. Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288–1295. Thus far, the most compelling mechanistic evidence of adiponectin function. This group demonstrates that gAdiponectin treatment of animals leads to rapid, transient phosphorylation of AMPK in muscle, whereas treatment with full-length ligand leads to similar effects in both muscle and liver. Furthermore, this group demonstrates phosphorylation of ACC in both muscle and liver, leading to fatty acid oxidation, glucose uptake, and lactate production in myocytes and downregulation of gluconeogenic enzymes in liver.

    Article  PubMed  CAS  Google Scholar 

  38. Winder WW, Hardie DG: AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999, 277:E1-E10.

    PubMed  CAS  Google Scholar 

  39. Hardie DG, Carling D, Carlson M: The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998, 67:821–855.

    Article  PubMed  CAS  Google Scholar 

  40. Fujii N, Hayashi T, Hirshman MF, et al.: Exercise induces isoform-specific increase in 5′AMP-activated protein kinase activity in human skeletal muscle. Biochem Biophys Res Commun 2000, 273:1150–1155.

    Article  PubMed  CAS  Google Scholar 

  41. Lochhead PA, Salt IP, Walker KS, et al.: 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000, 49:896–903.

    Article  PubMed  CAS  Google Scholar 

  42. Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487–37491.

    Article  PubMed  CAS  Google Scholar 

  43. Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296–1301.

    PubMed  CAS  Google Scholar 

  44. Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation 2001, 103:1057–1063.

    PubMed  CAS  Google Scholar 

  45. Arita Y, Kihara S, Ouchi N, et al.: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893–2898.

    Article  PubMed  CAS  Google Scholar 

  46. Yokota T, Oritani K, Takahashi I, et al.: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723–1732.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology and Diabetes Research and Training Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, 10461, Bronx, NY, USA

    Philipp E. Scherer hD

Authors
  1. Utpal B. Pajvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philipp E. Scherer hD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pajvani, U.B., Scherer, P.E. Adiponectin: Systemic contributor to insulin sensitivity. Curr Diab Rep 3, 207–213 (2003). https://doi.org/10.1007/s11892-003-0065-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-003-0065-2

Keywords

Search

Navigation